Nvision, a medical device and biologics developer focused on spinal implants, launched with four initial products that combine implants, instrumentation, biologics and high-touch customer service surgeons, facilities and distributors.

By aligning with surgeon thought leaders, key researchers and development engineers from prestigious research institutions, Nvision ibelieves it is positioned to design, test, and bring to market new concepts.

“Innovation is often an overused word in the medical device industry, but we see many opportunities to innovate when we bring technologies from all industries to the science of medicine,” said Brian Kieser, Founder of Nvision and Managing Partner of Fountainhead Investment Partners. “For this company, we’ve brought together industry veterans with some of the most innovating thinkers, engineers and researchers in the country to develop new concepts around medical devices.”

The initial products received FDA approval in Fall 2014 and include four interbody fusion systems. nv(c)™ is an anterior cervical interbody fusion system; nv(t)™ is a transforaminal lumbar interbody fusion system; nv(p)™ is a posterior lumbar interbody fusion system; and nv(a)™ is an anterior lumbar interbody fusion system. The devices have multiple footprints to adapt to the general shape of the vertebral endplates. Each footprint is available in multiple heights to accommodate patient variability.

As Nvision develops its own innovative products, the company has key supporting partnerships to provide a complete array of device and biologic technologies for surgeons and distributors.